Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer’s trials
Despite a lack of results from the trials, the Vice President of the company says “we still think it was the right decision.”
WHO backs GLP-1 meds like Ozempic to treat obesity
The World Health Organization is backing GLP-1 medications for the treatment of obesity, which some advocates hope will open up access to the drugs and improve affordability. Brands such as Ozempic and Wegovy are already wildly popular in North America. »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS For breaking news, video, audio […]
WHO Issues First-Ever Guidelines for Use of GLP-1 Drugs to Treat Obesity
The WHO recommended GLP-1s as a treatment for obesity alongside a healthy diet and regular exercise. Milles Team/Stocksy New guidelines from the World Health Organization (WHO) recommend using GLP-1 medications to help manage obesity. The agency said the weight-loss drugs should be used in conjunction with a healthy diet and regular exercise. Experts say the […]
A genetic screen in enteroendocrine cells reveals mechanisms that control protein sensing and GLP-1 release
Enteroendocrine cells (EECs) are the principal nutrient sensors in the gastrointestinal (GI) tract and release hormones such as glucagon-like-peptide 1 (GLP-1) that modulate GI function and appetite. While some of the molecules involved in nutrient sensing within EECs have been described, there have been no systematic studies to map the relevant genes and pathways. Here, […]
Trump GLP-1 Deal ‘Move in Right Direction’
Trump’s deal with drug manufacturers lowering the cost of GLP-1s will expand coverage for many patients. Caroline Messer, MD, explains why she welcomes this deal. Medscape Gastroenterology
WHO backs use of GLP-1 drugs for weight loss, along with diet, exercise
WHO guidelines say GLP-1 drugs are effective as long-term treatment for obesity in adults, barring pregnant women, alongside diet, exercise interventions; call for equitable access to reduce global obesity costs
WHO: Long-Term GLP-1 Therapies Recommended for Adults With Obesity
TUESDAY, Dec. 2, 2025 — Long-term glucagon-like peptide-1 (GLP-1) therapies combined with intensive behavioral therapy are recommended for adults with obesity, according to a special communication from the World Health Organization published…
Fractyl Health says procedure can maintain weight loss after stopping GLP-1
Brainstem GLP-1 neurons modulate physiological satiation and drive sustained weight loss in obese mice
Glucagon-like peptide-1 receptor (GLP-1R) activation in the brain strongly reduces appetite, but most brain GLP-1Rs are not accessible for systemically administered GLP-1R agonists. Acute activation of nucleus tractus solitarius (NTS) GLP-1 neurons, targeting brain GLP-1Rs, strongly suppresses food intake separate from GLP-1R agonists. However, it is unknown if their chronic stimulation is a viable strategy […]
Will blockbuster obesity drugs revolutionize addiction treatment?
Nature, Published online: 02 December 2025; doi:10.1038/d41586-025-03911-x Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.